Family · Pharmaceutical analytical standards
Gadobutrol
A macrocyclic gadolinium-based contrast agent for magnetic resonance imaging, used to highlight lesions of the nervous system, breast and blood vessels; approved in Switzerland in 1998 and in the United States in 2011. This family brings together the active ingredient, pharmacopoeial impurities, nitrosamines and other impurities.
Did you know?It is formulated at a 1 molar concentration, higher than that of other gadolinium contrast agents: the same dose needs a smaller volume of liquid.
No product matches your search.
EDQM standards 2
The official European Pharmacopoeia standards for this family.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
